Clinical trial
Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer
NCT00047788 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00047788 |
|---|---|
| Title | Efficacy Study of ZD6474 to Treat Multiple Myeloma Cancer |
| Official title | A Phase Two Study of ZD6474 in Patients With Relapsed Multiple Myeloma |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | ZD6474, VEGF-receptor tyrosine kinase (KDR) |
| Enrollment | 30 |
| Start date | Oct 1, 2002 |
| Completion | May 1, 2004 |
| First posted | Oct 21, 2002 |
| Last update posted | Aug 24, 2016 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: